A Phase 1 interventional study of MK-2828 in Chronic Kidney Failure, End-Stage Renal Disease and Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 24 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 6th largest by enrollment, is the only one that started in 2026, is one of 10 in phase 1, and was the 12th registered.
2,114 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 24 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.
The main inclusion criteria include but are not limited to the following:
Severe Renal Impairment Participants:
ESRD on HD Participants:
The main exclusion criteria include but are not limited to the following:
Renal Impairment Participants:
Healthy Matched Control Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with severe renal impairment will receive a single dose of MK-2828 on Day 1
Drug: MK-2828
Participants with ESRD will receive a single dose of MK-2828 on Day 1 in each of 2 periods, with a washout of at least 14 days between doses.
Drug: MK-2828
Participants with normal renal function will receive a single dose of MK-2828 on Day 1
Drug: MK-2828
Oral administration
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of MK-2828 in Plasma
Blood samples will be collected to determine the AUC0-inf of MK-2828
Time frame: Pre dose and at designated time points up to 192 hours post dose
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of MK-2828 in Plasma
Blood samples will be collected to determine the AUC0-last of MK-2828
Time frame: Pre dose and at designated time points up to 192 hours post dose
Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of MK-2828 in Plasma
Blood samples will be collected to determine the AUC0-24 of MK-2828
Time frame: Pre dose and at designated time points up to 24 hours post dose
Maximum Plasma Concentration (Cmax) of MK-2828 in Plasma
Blood samples will be collected to determine the Cmax of MK-2828
Time frame: Pre dose and at designated time points up to 192 hours post dose
Time of the Maximum Observed Concentration (Tmax) of MK-2828 in Plasma
Blood samples will be collected to determine the Tmax of MK-2828
Time frame: Pre dose and at designated time points up to 192 hours post dose
Concentration at 24 Hours Postdose (C24) of MK-2828 in Plasma
Blood samples will be collected to determine the C24 of MK-2828
Time frame: At designated time points up to 24 hours post dose
Apparent Terminal Elimination Half-life (t1/2) of MK-2828 in Plasma
Blood samples will be collected to determine the t1/2 of MK-2828
Time frame: Pre dose and at designated time points up to 192 hours post dose
Apparent Total Plasma Clearance (CL/F) of MK-2828
Blood samples will be collected to determine the CL/F of MK-2828
Time frame: Pre dose and at designated time points up to 192 hours post dose
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of MK-2828 in Plasma
Blood samples will be collected to determine the Vz/F of MK-2828
Time frame: Pre dose and at designated time points up to 192 hours post dose
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 14 days
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 2 days
Area Under the Concentration-time Curve From Start to End of Dialysis (AUCD) of MK-2828
Blood samples will be collected to determine the AUCD of MK-2828
Time frame: Prior to hemodialysis (HD) and at designated time points until day 6
Area Under the Concentration-time Curve Determined from the Pre-dialyzer Line (AUCCa) of MK-2828
Blood samples will be collected to determine the during AUCCa of MK-2828 during the dialysis period
Time frame: Prior to hemodialysis (HD) and at designated time points until day 6
Area Under the Concentration-time Curve Determined from the Post-dialyzer Line (AUCCv) of MK-2828
Blood samples will be collected to determine the during AUCCv of MK-2828 during the dialysis period
Time frame: Prior to hemodialysis (HD) and at designated time points until day 6
Dialysis Clearance (CLD) of MK-2828 Based on Plasma
Blood samples will be collected to determine the CLD of MK-2828 based on plasma during the dialysis period
Time frame: Prior to hemodialysis (HD) and at designated time points until day 6
Hemodialysis Extraction Ratio (ER_D) of MK-2828
Blood samples will be collected to determine the ER\_D of MK-2828 during the dialysis period
Time frame: Prior to hemodialysis (HD) and at designated time points until day 6
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Mar 2026 to primary completion in Sep 2026, 5 months.
Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.
Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.